Northwest Biotherapeutics, Inc. (NWBO)
OQB · Healthcare · Biotechnology
$0.17
-1.00%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$287.1M
Shares Outstanding
1.71B
P/S (TTM)
132x
Exchange
OQB
Currency
USD
About Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 200K | 672K | 494K | 807K |
| Operating Income | (14.3M) | (13.5M) | (10.9M) | (11.6M) |
| Net Income | (26.8M) | 1.4M | (3.1M) | (9.2M) |
| Diluted EPS | $-0.02 | N/A | $0.00 | $-0.01 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Operating Income | (67.2M) | (55.5M) | (66.5M) | (59.9M) |
| Net Income | (105.0M) | (62.6M) | (83.8M) | (60.2M) |
| Diluted EPS | $-0.10 | $-0.06 | $-0.07 | $-0.04 |